MinervaX Hopes To Match Pfizer In Group B Streptococcus Vaccines Race
Raises €72m Ahead Of Phase III Program
The Danish biotech has secured more funding for a late-stage program to advance its vaccine against Group B streptococcus, which is in a race for approval with Pfizer's product.
You may also be interested in...
Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.
This year’s first designations under the European Medicines Agency’s priority medicines scheme have gone to a maternal vaccine for an infection in newborns and a treatment for an ultra-rare bone disorder.
Europe does not have a pricing environment that rewards innovation which improves outcomes for patients, according to Vas Narasimhan, although Germany seems to be the best of a bad bunch.